Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
2.840
+0.080 (2.90%)
At close: Jul 17, 2025, 4:00 PM
2.812
-0.028 (-0.99%)
After-hours: Jul 17, 2025, 4:21 PM EDT

Company Description

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.

Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.

The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy.

Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.

Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Adverum Biotechnologies, Inc.
Adverum Biotechnologies logo
CountryUnited States
Founded2006
IPO DateJul 31, 2014
IndustryBiotechnology
SectorHealthcare
Employees155
CEOLaurent Fischer

Contact Details

Address:
100 Cardinal Way
Redwood City, California 94063
United States
Phone650 656 9323
Websiteadverum.com

Stock Details

Ticker SymbolADVM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001501756
CUSIP Number00773U108
ISIN NumberUS00773U2078
Employer ID20-5258327
SIC Code2836

Key Executives

NamePosition
Dr. Laurent FischerPresident, Chief Executive Officer and Director
Linda M. Rubinstein M.A.Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Kishor Peter Soparkar J.D.Chief Operating Officer
Dr. Setareh Seyedkazemi Pharm.D.Chief Development Officer
Dr. Rabia Gurses Ozden M.D.Chief Medical Officer
Dr. R. Andrew Ramelmeier Ph.D.Chief Technology Officer
Dr. Romuald Corbau Ph.D.Chief Scientific Officer
Aneta FergusonGeneral Counsel
Dena HouseChief People Officer
Carla FiankanSenior Vice President of Regulatory Affairs

Latest SEC Filings

DateTypeTitle
Jul 16, 2025SCHEDULE 13G/AFiling
Jun 20, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 18, 20258-KCurrent Report
May 23, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 20, 2025SCHEDULE 13DFiling
May 15, 2025SCHEDULE 13G/AFiling
May 14, 202510-QQuarterly Report
May 14, 20258-KCurrent Report
May 6, 2025SCHEDULE 13G/AFiling
Apr 28, 2025ARSFiling